Decorporation MCM phase 1 clinical safety study
Ended Awarded Last action
- Contract number
- 75N93021F00001
- Awardee
-
Sri International UEI SRG2J1WS9X63
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $9,754,263
Award facts
- Contract value 100% obligated
- $9,754,263.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Menlo Park, CA 94025, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $839,113 | |
| Exercise an Option | $1,299,968 | |
| Exercise an Option | $1,256,454 | |
| Exercise an Option | $1,262,805 | |
| Funding Only Action | $1,635,257 | |
| Funding Only Action | $363,202 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $3,097,464 |
About this award
This is a $9,754,263.00 cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to SRI International, a non-profit research and development institute, for a Phase 1 clinical safety study on medical countermeasures for decorporation. The contract, which does not have a set-aside designation, covers the period through April 30, 2026.
SRI International has engaged several subcontractors for this effort, including Trialwise Inc. (a small disadvantaged business) for clinical regulatory services, CCS Associates (a woman-owned small business) for clinical trial management, and Lawrence Berkeley National Laboratory for research and development support. This contract is part of NIAID's broader medical countermeasures program, which aims to develop treatments and technologies to address biological threats.
Quick answers
Who was awarded contract 75N93021F00001?
75N93021F00001 was awarded to Sri International by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 1, 2021.
How much is contract 75N93021F00001 worth?
The government has obligated $9,754,263 on 75N93021F00001.
Is contract 75N93021F00001 an order under another contract?
Yes. 75N93021F00001 is a delivery order under 75N93020D00011, an indefinite delivery contract.
Was contract 75N93021F00001 competed?
The extent of competition for 75N93021F00001 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award